Nancy Lurker

CIK: 0001450485

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (10.3%)

Position reduction

Option Exercises (M)11 (28.2%)

Derivative conversions

Awards (A)9 (23.1%)

Compensation grants

Other (G, F, J, C, D, …)15 (38.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ALKS

Alkermes plc.

Director

COLL

COLLEGIUM PHARMACEUTICAL, INC

Director

EYPT

EyePoint, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (39 total)

ALKS
Alkermes plc.
May 21, 2026
Tax Payment(F)
Direct
1.5K shares at avg. $36.95$55K
ALKS
Alkermes plc.
May 21, 2026
Exercise(M)
Direct
6.1K shares-
ALKS
Alkermes plc.
May 20, 2026
Award(A)
Non Qualified Stock Option (Right to Buy)
Direct
11.5K shares-
ALKS
Alkermes plc.
May 20, 2026
Award(A)
Restricted Stock Unit Award
Direct
5.4K shares-
COLL
COLLEGIUM PHARMACEUTICAL, INC
May 14, 2026
Award(A)
Direct
8.7K shares-
COLL
COLLEGIUM PHARMACEUTICAL, INC
May 13, 2026
Sale(S)
Direct
4.5K shares at avg. $35.97$162K
ALKS
Alkermes plc.
Apr 11, 2026
Exercise(M)
Direct
3.8K shares-
ALKS
Alkermes plc.
Apr 11, 2026
Tax Payment(F)
Direct
901 shares at avg. $33.36$30K
EYPT
EyePoint, Inc.
Jan 6, 2026
Exercise(M)
Direct
75.1K shares-
EYPT
EyePoint, Inc.
Jan 5, 2026
Exercise(M)
Direct
12.7K shares-
EYPT
EyePoint, Inc.
Jan 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Dec 4, 2025
Sale(S)
Direct
9.3K shares at avg. $15.11$140K
EYPT
EyePoint Pharmaceuticals, Inc.
Nov 28, 2025
Sale(S)
Direct
500 shares at avg. $14.95$7K
EYPT
EyePoint Pharmaceuticals, Inc.
Nov 26, 2025
Sale(S)
Direct
200 shares at avg. $14.95$3K
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 10, 2025
Exercise(M)
Direct
11.1K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Direct
31.2K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Direct
27.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Indirect
15.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Direct
15.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Indirect
103.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Direct
103.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Indirect
55K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Indirect
27.3K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Indirect
31.2K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Jul 2, 2025
Gift(G)
Stock Option (Right to Buy)
Direct
55K shares-

		Type	Shares	Price		Ownership
May 21, 2026	ALKS Alkermes plc.	Tax Payment(F)	1,475	$36.95	$54,501	Direct
May 21, 2026	ALKS Alkermes plc.	Exercise(M)	6,142	-	$0	Direct
May 20, 2026	ALKS Alkermes plc.	Award(A) Non Qualified Stock Option (Right to Buy)	11,538	-	-	Direct
May 20, 2026	ALKS Alkermes plc.	Award(A) Restricted Stock Unit Award	5,409	-	-	Direct
May 14, 2026	COLL COLLEGIUM PHARMACEUTICAL, INC	Award(A)	8,741	-	$0	Direct
May 13, 2026	COLL COLLEGIUM PHARMACEUTICAL, INC	Sale(S)	4,500	$35.97	$161,861	Direct
Apr 11, 2026	ALKS Alkermes plc.	Exercise(M)	3,751	-	$0	Direct
Apr 11, 2026	ALKS Alkermes plc.	Tax Payment(F)	901	$33.36	$30,057	Direct
Jan 6, 2026	EYPT EyePoint, Inc.	Exercise(M)	75,133	-	$0	Direct
Jan 5, 2026	EYPT EyePoint, Inc.	Exercise(M)	12,666	-	$0	Direct
Jan 2, 2026	EYPT EyePoint, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Dec 4, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Sale(S)	9,300	$15.11	$140,477	Direct
Nov 28, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Sale(S)	500	$14.95	$7,475	Direct
Nov 26, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Sale(S)	200	$14.95	$2,990	Direct
Jul 10, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Exercise(M)	11,111	-	-	Direct
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	31,165	-	-	Direct
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	27,270	-	-	Direct
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	15,278	-	-	Indirect
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	15,278	-	-	Direct
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	103,308	-	-	Indirect
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	103,308	-	-	Direct
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	55,000	-	-	Indirect
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	27,270	-	-	Indirect
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	31,165	-	-	Indirect
Jul 2, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Gift(G) Stock Option (Right to Buy)	55,000	-	-	Direct

1-25 of 39 transactions

About Lurker Nancy

Lurker Nancy (SEC CIK 0001450485) files insider reports with the SEC as Director of Alkermes plc. (ALKS), Director of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Director of EyePoint, Inc. (EYPT).

Signal8 holds 18 ownership filings by Lurker Nancy (1 Form 3, 17 Form 4), filed between Jan 7, 2025 and May 22, 2026. Those filings report 39 transactions, from Jan 3, 2025 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lurker Nancy's filings is in DUBLIN.

Recent filings by Lurker Nancy

May 21, 2026: Tax withholding of ALKS shares (Form 4, code F).
May 21, 2026: Option exercise of ALKS shares (Form 4, code M).
May 20, 2026: Grants or awards of ALKS derivative securities (2 lines, Form 4, code A).
May 14, 2026: Grant or award of COLL shares (Form 4, code A).
May 13, 2026: Open-market sale of COLL shares (Form 4, code S).

Other insiders filing for Alkermes plc. (ALKS)

Reed Joshua, SVP, Chief Financial Officer
Whitaker Anne Clem, Director
Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
Hopkinson Craig C., EVP R&D, Chief Medical Officer
Nichols Christian Todd, SVP, Chief Commercial Officer
Jackson Blair Curtis, President & CEO, Alkermes plc

How to read Form 4 transaction codes